Key result
Nitric oxide synthases drive peripheral pain chronicity and offer targets for personalized pharmacotherapy.
Why the study?
Standard treatments do not resolve chronic pain, prompting the search for personalized strategies, with the nitric oxide system potentially playing a key role in peripheral pain development and chronicity.
Does modulation of the nitric oxide (NO) system and NOS isoforms improve pain management in patients with chronic peripheral pain syndromes?
Does modulation of the nitric oxide (NO) system and NOS isoforms improve pain management in patients with chronic peripheral pain syndromes?
Understanding the complex pro- and antinociceptive roles of NO and NOS isoforms provides a foundation for developing targeted, personalized non-opioid therapies for chronic peripheral pain.
Answers are grounded in this paper and cite their sources.
Does not support routine NOS modulation in chronic peripheral pain; leaves open personalized pharmacotherapy pending prospective trials.
Chronic pain syndromes are an important medical problem generated by various molecular, genetic, and pathophysiologic mechanisms. Back pain, neuropathic pain, and posttraumatic pain are the most important pathological processes associated with chronic pain in adults. Standard approaches to the treatment of them do not solve the problem of pain chronicity. This is the reason for the search for new personalized strategies for the prevention and treatment of chronic pain. The nitric oxide (NO) system can play one of the key roles in the development of peripheral pain and its chronicity. The purpose of the study is to review publications devoted to changes in the NO system in patients with peripheral chronical pain syndromes. We have carried out a search for the articles published in e-Library, PubMed, Oxford Press, Clinical Case, Springer, Elsevier, and Google Scholar databases. The search was carried out using keywords and their combinations. The role of NO and NO synthases (NOS) isoforms in peripheral pain development and chronicity was demonstrated primarily from animal models to humans. The most studied is the neuronal NOS (nNOS). The role of inducible NOS (iNOS) and endothelial NOS (eNOS) is still under investigation. Associative genetic studies have shown that single nucleotide variants (SNVs) of NOS1, NOS2, and NOS3 genes encoding nNOS, iNOS, and eNOS may be associated with acute and chronic peripheral pain. Prospects for the use of NOS inhibitors to modulate the effect of drugs used to treat peripheral pain syndrome are discussed. Associative genetic studies of SNVs NOS1, NOS2, and NOS3 genes are important for understanding genetic predictors of peripheral pain chronicity and development of new personalized pharmacotherapy strategies.
No takes yet. Share an insight, caveat, or question.
Shnayder et al. (2021) conducted a review in Chronic peripheral pain syndromes. Nitric oxide (NO) and NOS modulators was evaluated. The nitric oxide system and single nucleotide variants of NOS genes play a key role in the development and chronicity of peripheral pain, presenting a potential target for personalized pharmacotherapy.
Synapse has enriched 10 related papers. Consider them for comparative context: